Across
- 5. Most common toxicity with triplet therapy.
- 6. burden Key message with Q1 promo item
- 7. Nr of trials in STOPCAP MA
- 9. Meta-analysis presented at ASCO GU 2025
- 10. Main author of PEACE 1
- 11. ADT + ARPI + ____
- 13. Goal with Q1 customers
Down
- 1. grading score for prostate cancer
- 2. Stampede was done in ___ patients
- 3. Teronred daily dosage
- 4. An AMIDE
- 8. Androgen Receptor ____ Inhibitor
- 12. What will Teronred's contribution be to onco portfolio?